Many studies have investigated the clinicopathologic and molecular characteristics of HER2-low breast cancer, but no clear consensuses regarding prognostic effects have been reached, and intensive studies on mutation patterns in patients with different HER2 expression levels are still limited [7, 10, 11]. The gene discussed is ERBB2; the disease is breast carcinoma.